key: cord-0889566-hw96gf0d authors: Ducloux, Didier; Colladant, Mathilde; Chabannes, Melchior; Bamoulid, Jamal; Courivaud, Cécile title: Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients date: 2021-07-08 journal: Clin Kidney J DOI: 10.1093/ckj/sfab125 sha: dee559c0402b04ce1a42dd4e8890a90b64b62fdc doc_id: 889566 cord_uid: hw96gf0d nan Estimated glomerular filtration rate (eGFR) was lower in non-responders [48 (32-58) versus 62 (38-81) mL/min/1.73 m 2 , P < 0.001]. Antibody titers were strongly related to eGFR Non-responders were more frequently under mycophenolic acid (MPA) (76% versus 32%, P < 0.001), whereas responders were more likely to receive mTOR inhibitors (mTORi) (36% versus 6%, P < 0.001). There was a trend towards fewer use of belatacept in responders (0% versus 6%, P ¼ 0.047). Calcineurin inhibitors (CNIs) use was similar in responders and nonresponders (Table 1) . CD3, CD4 and CD8 counts were lower in non-responders (Table 1) . Using multiple logistic regression, shorter transplant duration (P ¼ 0.003), lower eGFR (P < 0.001), MPA use (P < 0.001) and lower CD4 count (P ¼ 0.016) were all associated with lack of response to vaccine ( Table 2 ). This model strongly predicts vaccine response [area under the curve 0.89 (0.82-0.93), P < 0.001] (Figure 1 ). Complete absence of response to vaccine was associated with low CD4 count (P ¼ 0.049) and reduced eGFR (P ¼ 0.006). Robust vaccine response was associated with better eGFR (P < 0.001), longer transplant duration (P < 0.001) and no MPA use (<0.001). We report in a single-centre study that only half of KTR have a vaccine response after two doses of BNT162b2 mRNA COVID-19 vaccine. We observed that some factors are strongly associated with vaccine response. Patients receiving MPA had a lower rate of vaccine response. MPA inhibits both T-and B-cell proliferation. Previous studies reported similar results [3, 4] . Reduced response to other vaccines has been also reported in patients under MPA when compared with those receiving CNI [5] [6] [7] . Reduced renal function diminishes the likelihood of achieving seroprotection after complete vaccine. Similar results have been observed for H1N1 vaccination [7] . The mechanisms are not very clear, since significant humoral response is reported in about 90% of dialysis patients [8] . Low CD4 T-cell counts were associated with reduced response to vaccine. Post-transplant low CD4 counts indicate accelerated immune senescence and are associated with increased risk of cancer and infection [9] . We showed that four risk factors explain 90% of response likelihood to BNT162b2 mRNA COVID-19 vaccine in KTR. These factors are not modifiable except for MPA use. Better strategies of vaccination as well as reinforced barrier measures are required in KTR. Letter to the Editor | 2271 Is COVID-19 infection more severe in kidney transplant recipients? Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: A prospective cohort study Comparison of the immunogenicity of Dukoral V R oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate-a controlled trial Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation None declared.